Category Archives

8 Articles

Sign Up to Receive Updates

Science in Service of Humanity

Genes are ancestor based. Metabolites are how you are doing now.

If you are curious to be updated on our research please check the Research News section on the SISOH website. This is the most up to date information. You can subscribe to this blog by inputting your email in the subscription box on the sidebar.

 

Health Rising – Recovery Potentially Possible: Naviaux Talks on Chronic Fatigue Syndrome (ME/CFS)

by Cort Johnson | Dec 13, 2016

Personalized treatment plans will require addressing the core metabolic abnormalities found in most ME/CFS patients plus the individual metabolic issues found of each patient.

Treatments that work for a time and then stop could be the result of not addressing all the metabolic needs of an individual.

Cort Johnson – “Recovery Potentially Possible: Naviaux Talks on Chronic Fatigue Syndrome (ME/CFS)”

The day after my brother’s wedding I shot down to San Diego to meet Rachel Riggs and a doctor with ME/CFS. Rachel, who has turned into a volunteer patient coordinator had enrolled me in Naviaux’s next metabolomics study. (Resistance, I quickly surmised, was futile – not that I was putting up any.) Rachel chatted away on the phone with another potential participant as we drove down to Naviaux’s lab. I was one of the last to give blood. editor’s note: Cort actualy enrolled in the 2nd Metabolomics study. SISOH is now recruiting for a 3rd study.

After I gave a surprising small amount of blood we tromped down the hall to meet with Dr. Naviaux in his workroom, the industrial looking pipes overhead bringing back memories of college labs in the past. Ducking into one lab Rachel showed me two $500,000 dollar mass spectometer machines each the size of a large microwave.

Gracious, as always, Dr. Naviaux offered us some coffee or tea. A bit spacey from my fast I tried out some green tea – at which point my nose immediately stopped up. At the first sound of my sniffles Naviaux turned to me and said we would have to note that for the study. (No one with a cold is allowed in the study.) Those sniffles cleared up later. (Dr. Naviaux, if you read this I promise it was from the tea…)

Read More

MEDSCAPE – Biomarker Research Advances in ‘Chronic Fatigue Syndrome’

Miriam E. Tucker
Medscape – November 08, 2016

In addition, in an “unbiased” metabolomics study using mass spectrometry, metabolites that differed most between 17 patients with ME/CFS and 15 healthy participants involved pathways harvesting energy from glucose, fatty acids, and amino acids.

The finding, suggestive of a general hypometabolic state, corresponds to another recent study published in the Proceedings of the National Academy of Sciences. The specific metabolites differed between the two studies, but, Dr Komaroff said, “it’s consistent. It says that some types of metabolic pathways are downregulated in this illness, whereas others like those involving immunity and inflammation are upregulated.”

FORT LAUDERDALE, FL — New research adds to growing evidence that the illness commonly known as chronic fatigue syndrome is biologically based, researchers report here at the International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (IACFSME) research and clinical conference. Some of the abnormalities identified suggest potential clinical diagnostic tests and targeted treatments.

The condition, now called myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) by US government bodies, has long confounded the medical community because, although patients may be severely debilitated and exhibit numerous abnormal physical findings, no specific biomarker has been found to conclusively make the diagnosis.

Read More

Metabolomics Study Update 12/14/16

From Asha Baxter
AIMS Research Coordinator

We are finished with the blood collection for the 2nd study! This is the replication study of the intial “Metabolic features of chronic fatigue syndrome,” with the replication testing being done with Dr. Paul Cheney’s patients. The blood samples are all in and have been shipped to the Naviaux lab to be analyzed. Very exciting accomplishment since the 1st study took a great deal longer to get samples in. We are moving in a upward and onward direction. Metabolic results and a new published study should be expected in 2017.

We also have found a device that stores and holds blood for shipping so we can start collecting samples from around the world. We know that we have a growing community of individuals who would like to participate in our AIMS research from over seas. We are still in testing mode with this and will update when we have confirmation that the container safely transfers blood.

If you would like to participate in the Analyzing Individual Metabolimics Study (AIMS), sign up now to be placed on the list.

MyLymeData 3-month follow-up survey launched

MyLymeData

From Lorraine Johnson, JD, MBA at LYMEPOLICYWONK

Originally published on LymePolicyWonk on November 15, 2017

Last year, LymeDisease.org launched MyLymeData–a national patient-centered big data project. Today it is the largest study of Lyme patients ever conducted, with over 6,000 currently enrolled. Our goal is 10,000 participants. MyLymeData allows patients to pool their data to help find a cure.

This week we are rolling out MyLymeData’s three-month follow-up survey, which tracks patient symptoms, treatments, treatment response, and functional status on a quarterly basis. This survey holds the key to questions patients care about. What treatments work? Why do they work for some people and not others?

The three-month survey also seeks to find out whether patients with Lyme disease tend to have other related diseases, like Parkinson’s disease or lupus. We ask about whether Lyme disease runs in the family. Do mothers pass it along to their children? Is it passed from husband to wife?

Read More

More from Dr. Naviaux on metabolics and Chronic Fatigue Syndrome

Dr. Naviaux has responded to some comments on the groundbreaking paper, “Metabolic Features of Chronic Fatigue Syndrome”.

In this response he addresses the need for metabolic studies in other disease groups, whether metabolic studies determine the initial cause of sysmptoms, and how dauer states relate to what is seen in CFS.

We thank Vogt et al. for their comments (1). We respond to their three points in order. First, we are aware of the need to extend future metabolomics studies to include other disease groups. We stated this fact in the discussion of ref. 2 and are validating the results in independent cohorts. The detailed biochemical phenotype or signature that we found provides a first glimpse at a previously hidden biology. For example, disturbances in sphingolipid metabolism have important implications for immunobiology and neuroendocrine regulation relevant to myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) (3). Sphingolipids are important mediators of the cell danger response (CDR) (4), and the CDR is an important regulator of the behavioral and functional changes produced by infection, and associated with sickness behavior (5). The biochemical phenotype of ME/CFS is distinct from other diseases that Vogt et al. (1) named. For example, in heart failure, metabolomics shows that long chain acyl-carnitines are increased (6), but these long chain acyl-carnitines were not changed in ME/CFS (2). In our view, chemistry and metabolism underlie all aspects of human biology. Our studies show that metabolomics can be used as a new lens to reveal unexpected biology that was invisible before…

Robert Naviaux, et all

Read full response.
Read the letter the response was based on.

PARTICIPATE in metabolomics research at SISOH.

Support CFS/ME Research by Shopping at AmazonSmile

Now you can support Gordon Medical’s research into CFS/ME and other chronic illness by shopping at AmazonSmile. Just use the link here in the post and your purchases will help support Gordon Medical Research Center’s fundraising efforts. For eligible purchases at AmazonSmile, the AmazonSmile Foundation will donate 0.5% of the purchase price to the customer’s selected charitable organization. AmazonSmile is the same Amazon you know. Same products, same prices, same service.

We hope you select us!

 

We are currently fundraising for the Analyzing Individual Metabolomics Study (AIMS), our third research study on the use of metabolomics in CFS/ME. Our first study resulted in the ground breaking research, “Metabolic features of chronic fatigue syndrome,” published in the Proceedings of the National Academy of Sciences. Our second study, a replication study with a larger group of CFS patients, has completed enrollment, and is processing the data collected. Our thirds study, AIMS, is now recruiting participants and fundraising. We will be looking at how comprehensive metabolomics analysis can be used to evaluate CFS/ME. AIMS builds on our previous studies, which have demonstrated there is a clear metabolomic profile in patients with CFS/ME. The more funds we are able to raise, the more participants we can include in this important research. To find out more about our research, or to sign up to participate, go to our research website at Science in Service of Humanity (SISOH). You can also make a tax deductible donation directly to the Gordon Medical Research Center.

The Most Important and Groundbreaking Study of ME/CFS to Date

 in Clinical Pain Advisor
September 27, 2016

Metabolomic Deficiencies Characteristic of Chronic Fatigue Syndrome

In a study designed to test the utility of targeted metabolomics in the diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), researchers identified a unique chemical signature that differentiates affected patients from healthy individuals.

Ronald W. Davis, PhD, director of Stanford Chronic Fatigue Syndrome Research Center of Stanford University School of Medicine commented on the findings of Dr. Naviaux’s group on the the Open Medicine Foundation website, where he serves as director of the Scientific Advisory Board.

“It is the most important and groundbreaking study of ME/CFS to date. Extending recent indications of metabolic alterations in ME/CFS, this study provides the first comprehensive, quantitative demonstration of the metabolomic deficiencies that characterize the disease.”

Read More